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Treatment of ocular surface squamous neoplasia with
Mitomycin C
A Gupta,1 J Muecke1,2
ABSTRACT
Aim To report the outcome of treatment of non-invasive
ocular surface squamous neoplasia (or conjunctival-
corneal intra-epithelial neoplasia (CCIN)) where topical
mitomycin C (MMC) has been used in the treatment
regimen.
Design Prospective, non-comparative interventional
case series.
Participants 91 primary or recurrent CCIN lesions from
90 patients treated in a single ocular oncology centre
over a 10.5-year period.
Intervention 73 cases of localised, non-invasive CCIN
and eight cases of recurrent CCIN received a treatment
regimen of surgical excision6cryotherapy, followed by
two to three 1-week cycles of adjuvant topical MMC
(0.04% four times a day). 10 cases of diffuse CCIN
received two to three 1-week cycles of topical MMC
(0.04% four times a day) as sole primary treatment.
Main outcome measure Successful treatment was
defined as no clinical recurrence of CCIN.
Results Mean follow-up of 56.8 months (range 5.8 to
119.8) and median 57.3 months, revealed no
recurrences (0%) in the localised primary group, and one
persistent case and two recurrences (30%) in the diffuse
primary group. There was one recurrence (12.5%) in the
recurrent group, but this was in the only eye with
a diffuse type of recurrence.
Conclusions MMC treatment following surgical excision
appears to decrease the recurrence rate of localised
CCIN and should be considered as adjuvant therapy in
primary treatment. MMC should also be considered as
adjuvant therapy in the treatment of localised recurrent
disease. MMC may be used as sole therapy in more
diffuse disease, but close ongoing follow-up is
recommended in view of the significant risk of persistent
or recurrent disease.
Ocular surface squamous neoplasia (OSSN) is
a spectrum of dysplastic disease of the cornea and
conjunctiva ranging from carcinoma-in situ
(conjunctival-corneal intra-epithelial neoplasia
(CCIN)) to invasive squamous cell carcinoma
(SCC). It is reported to be a common malignancy of
the ocular surface, particularly in areas with high
ultraviolet light exposure.1 Currently, there are
many suggested treatment options including
surgical excision with or without cryotherapy,1e3
radiotherapy,4e6 excimer laser,7 topical mitomycin
C (MMC),3 8e15 topical 5-ﬂuorouracil (5-FU),16 17
and perilesional and topical interferon a 2b (IFA
2B).18e20
MMC is a well-established treatment modality
for CCIN. It has been reported to be efﬁcacious as
primary and adjuvant therapy.3 8e15 The authors
present a large series of 91 eyes aiming to report the
outcome of the treatment of CCIN where MMC
has been used in the treatment regimen.
METHODS
Statistics
A prospective, non-comparative interventional case
series of 91 eyes with primary or recurrent CCIN
lesions in 90 patients was undertaken. All cases
were treated in a single ocular oncology centre over
a 10.5-year period between November 1998 and
April 2009. The patients with recurrent lesions had
all received primary treatment elsewhere.
Definitions
CCIN lesions were classiﬁed into three main cate-
gories: localised primary, diffuse primary and
recurrent (table 1). The arbitrary cut-off level of less
than or equal to 5 clock hours as a deﬁnition for
localised disease was made by the authors due to
their concern of the increased risk of limbal stem
cell failure if 1808 or more of limbus was damaged
(based on personal experience and presented at
International Congress of Ocular Oncology, Phila-
delphia, May 1999). Diffuse disease of over 5 clock
hours of limbal involvement was therefore consid-
ered too hazardous to excise.
Method of diagnosis
The method of diagnosis varied depending on the
lesion type. Localised and recurrent lesions were
diagnosed primarily by excision biopsy and diffuse
lesions by multiple incision biopsies or impression
cytology.
Treatment
Treatment of all cases was carried out by a single
ocular oncologist (JM). The treatment regimens for
localised, diffuse and recurrent CCIN are summar-
ised in table 1. Excision involved complete superﬁ-
cial dissection (not lamellar) from the cornea and
limbus with a 2 mm margin on the conjunctival
aspect. Double freezeethaw cryotherapy with
a nitrous oxide cryoprobe was applied to the limbal
base and to the full thickness of the elevated
conjunctival edge in the majority of patients. All
patients were treated with chloramphenicol and
prednisolone acetate 1% eye-drops four times daily
until wound healing was complete.
MMC 0.04% (0.4 mg/ml) four times a day was
used on a week-on week-off basis for two to three
cycles (one cycle of treatment¼1 week on+one
week off). Table 2 shows the number of cycles of
treatment received by patients. Three patients with
difﬁcult access to the treatment centre were treated
with a continuous 2-week course of MMC.




and Visual Sciences, University
of Adelaide, Adelaide, Australia
Correspondence to






Accepted 18 November 2009
Br J Ophthalmol 2010;94:555e558. doi:10.1136/bjo.2009.168294 555
Clinical science
 group.bmj.com on January 9, 2013 - Published by bjo.bmj.comDownloaded from 
Treatment was only commenced after complete epithelial
healing in cases with prior excision. Punctal plugs were not used
in any of the cases.
Follow-up
Patients were examined at 1 month and 3 months following
completion of MMC treatment, then at 6-monthly intervals for
2 years, then yearly for a total of 5 years (indeﬁnitely if diffuse
disease). The primary outcome measure was no clinical recur-
rence of CCIN.
RESULTS
Ninety-one eyes from 90 patients were enrolled in the study.
The age of patients ranged from 41 to 87 years (median
66 years). There were 70 males and 20 females in the study, and
51 right and 40 left eyes were treated. The minimum follow-up
interval was 5.8 months. All but one patient had a minimum
follow-up of 12 months. The one patient with 5.8 months’
follow-up was included, as there was evidence of recurrent
disease at this time. The mean follow-up was 56.8 months
(median 57.3 months, range 5.8 to 119.8). All lesions involved
the limbus, and there were no patients in this series with
involvement of the non-bulbar conjunctiva. Table 2 presents the
number and percentage recurrence rates of CCIN.
No recurrences were noted in the localised group (73 eyes in
total). There was one eye in the localised group where a new
separate focus of disease was noted. This responded to 5-FU 1%
four times daily for 2 weeks. In the diffuse group (10 eyes in
total), there was one case with persistent disease (partial
regression) and two with recurrence. The diffuse persistent
lesion was subsequently successfully treated with topical 5-FU
1% four times a day for 2 weeks. Of the two diffuse lesions that
showed recurrence, the one with diffuse recurrence responded to
5-FU, and the one with a more localised recurrence responded to
local excision. There have been no further recurrences in these
patients to date. In the recurrent group, there was one recur-
rence in the only patient with a diffuse type of recurrence of
a diffuse lesion previously treated with 5FU. This patient is
currently awaiting treatment with topical IFA 2B. All patients
with localised recurrent lesions responded to excision, cryo-
therapy and MMC.
There were no serious complications noted in this study. A
localised allergic reaction was seen in 23% of patients during the
second or third cycle of treatment but settled rapidly on cessa-
tion of treatment in all. Of these patients, one developed
a secondary levator disinsertion ptosis requiring surgical
correction. Fifteen per cent of patients developed epiphora, most
of which settled following simple syringing of the involved
nasolacrimal system. Of these patients, one developed the
epiphora only 3 years after treatment with MMC and therefore
may be unrelated. Another patient subsequently required
a dacryocystorhinostomy (DCR) but also required a DCR in the
contralateral eye that did not receive treatment. Finally, two
patients with diffuse disease developed a corneal epithelial
defect but no stromal melt. There were no incidences of severe
complications such as hypotony, corneo-scleral melt or limbal
stem cell failure.
DISCUSSION
To our knowledge, this is the largest series of primary and
recurrent CCIN lesions treated with MMC as adjuvant or sole
therapy. The authors note that better control is achieved for
localised compared with diffuse disease (recurrence rate 0% vs
30%). For localised disease, the best control is achieved with
excision and cryotherapy followed by topical MMC (no recur-
rences in 73 eyes).
Excision remains an important step in management of local-
ised CCIN. The authors prefer primary excision where possible,
Table 1 Lesion types
Lesion type Definition Treatment regimen
Localised primary conjunctival-
corneal intra-epithelial neoplasia
Excisable limbal lesions (with
associated conjunctival and corneal
involvement) 5 clock hours or less
Excision+cryotherapy+MMC 0.04%
four times daily 7 days32e3 cycles
Diffuse primary conjunctival-corneal
intra-epithelial neoplasia
Limbal lesions (with associated
conjunctival and corneal involvement)
greater than 5 clock hours




Recurrent limbal lesions (with
associated conjunctival and corneal
involvement); all but one were
localised and excisable in this series
Excision+cryotherapy+MMC 0.04%
four times daily 7 days33 cycles (the
diffuse recurrence was treated with
MMC 0.04% four times daily
7 days33 cycles)
One cycle of mitomycin C (MMC) treatment¼1 week on+1 week off.





















72 73 47* 25* 0 0%
Diffuse primary
(>5 clock hours)
10 10 2 8 Two recurrent
One persistent
30%
Recurrent 8 8 4 4 1 12.5%
One patient was included in both localised and recurrent group, since the two eyes had different conjunctival-corneal intra-epithelial
neoplasia types.
*One eye in this group received only one treatment cycle.
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as it allows an immediate histopathological diagnosis and
excludes life-threatening invasive malignancies such as SCC or
amelanotic malignant melanoma.3 It also helps to exclude
masquerading lesions such as viral papilloma, where MMC is
not effective, and keratoacanthoma and solar keratosis, where
MMC is not necessary. Surgical debulking of the lesion makes
adjuvant treatment more effective, as MMC is being utilised
against a lower tumour load.
The disadvantage of primary excision alone is the high
recurrence rate, which ranges from 15% to 52%.1 CCIN may also
be a multifocal disease. Impression cytology studies have
revealed that areas of clinically normal limbus remote from the
tumour may be positive for dysplasia. Localised surgery does not
address these areas of possible preclinical dysplasia;15 therefore,
numerous topical adjuvant treatments have been described in an
attempt to decrease the rate of recurrence. The authors believe
that the combination of excision (with or without adjuvant
cryotherapy) followed by MMC has resulted in the absence of
recurrences seen in their series of cases with localised excisable
disease.
When treating disease involving more than ﬁve clock hours of
limbus, excision is potentially hazardous due to the risk of
limbal stem cell failure,21 and so is avoided by the authors.
MMC is used as sole therapy for cases with diffuse limbal
involvement. There have been no cases of complicating limbal
stem cell failure in this series. However, the lack of prior
surgical debulking resulted in the higher persistence and recur-
rence rates noted in cases with diffuse disease. Fortunately, all
but one of these cases responded to subsequent treatment with
topical 5FU or excision and have remained free of further
recurrences.
Intraoperative cryotherapy is commonly used as adjuvant
therapy,1e3 as it is known to decrease the recurrence rate by
destruction of any residual tumour tissue beyond the horizontal
or deep surgical margins of the wound.22 Chen and Muecke,3
however, found no difference in the recurrence rate of localised
CCIN in patients who received cryotherapy compared with
those who did not, when MMC was also used as adjuvant
treatment. The authors continue to use cryotherapy to the
limbal base because of the possibility of invasive disease deep to
the excision margin.
Topical MMC provides an alternative to extensive and
repeated surgery for CCIN, and its use has also been reported in
a number of smaller studies. The results have been summarised
in table 3 and compared with the current study. These studies all
support a role for utilising MMC in the treatment of CCIN.
One of the major limitations of topical MMC therapy is the
lack of a recommended optimal dose and duration of treatment.
Previous studies have used 0.02 or 0.04% concentrations for
durations of 1e5 weeks (results outlined in table 3). The
strength of this study lies in the fact that it is largest reported
cohort of patients all treated with a standard dose of MMC of
0.04%. The lack of major complications is supportive of this
treatment regime.
The rationale for the authors’ regimen of adjuvant MMC is to
use the highest tolerable concentration of chemotherapy (0.04%)
against the lowest possible residual tumour load. Limbal toxicity
from MMC has been reported;23 hence, a week-on week-off
regime is used to minimise toxicity to normal healthy ocular
surface and periocular tissues, especially limbal stem cells. In
a previously published study by Khong and Muecke,24 there
were no serious complications noted in a similar number and
spectrum of patients.
Other topical chemotherapy agents have been used such as
5-FU16 17 and IFA 2B.18e20 Yeatts et al17 evaluated the efﬁcacy of
pulse dosing of 5-FU in the treatment of CCIN in a prospective,
non-comparative case series. Seven patients were treated with
5-FU 1% for an average of 3.75 cycles (range 2 to 5 cycles). Three
patients had disease recurrence with a mean follow-up period of
18.5 months.17 Some studies have shown success with 5-FU in
cases refractory to MMC.16 The success of 5-FU in these studies
and in ours (when treating persistent or recurrent disease)
suggests effectiveness of 5-FU due to a difference in the mech-
anism of cytotoxicity of the two agents.16
IFA 2B has been used with favourable outcomes in primary
and recurrent cases of CCIN. The above studies, however,
indicate that IFA 2B requires a longer duration of treatment
(1e10 months)18e20 than is required with MMC, which may be
a disadvantage. However, IFA 2B may be useful in cases resistant
to MMC or 5FU.
In conclusion, this is the largest study evaluating the treat-
ment of CCIN where MMC has been used in the regimen. There
were few recurrences and no serious complications. MMC
treatment following surgical excision of primary or recurrent
localised CCIN appears to decrease the recurrence rate. A higher
incidence of persistent or recurrent disease is noted when MMC









Frucht-Perry et al9 3 0.02% four times daily for
10e22 days
0% recurrence 4e12





Frucht-Perry et al8 17 0.02e0.04% four times daily for
7e28 days
35% recurrence NA
Daniell et al11 20 0.02e0.04% four times daily for
1e5 weeks in alternate weeks
20% recurrence 3e26
Shields et al10 10 0.04% four times daily for
1e4 weeks in alternate weeks
0% recurrence 6e50
Hirst et al15 26 0.04% four times daily for
3 weeks
0.8% recurrence 6e12
Current study 91 0.04% four times daily for
2e3 weeks in alternate weeks
0% recurrence in localised, 12.5%
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is used as sole therapy for diffuse disease. However, to avoid
potential damage to limbal stem cells from extensive excision,
MMC may be used as sole therapy but close ongoing follow-up
is recommended in view of the signiﬁcant risk of recurrence.
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